

FOUNDATION MEDICINE ANNOUNCES

A Call for Grants Notification (CGN)

Focused on Disparities in Biomarker Testing



Karen is part of Foundation Medicine Patient Network and was compensated for her participation in a photo shoot.

Precision therapies, driven by actionable biomarkers, represent advances and hold promise for people diagnosed with cancer.¹ With each new advance in precision medicine, we can inadvertently create education, awareness, and access gaps. Well-documented barriers to equitable cancer care exist in many areas, including inequitable access to genomic testing.^{2,3}

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research and is committed to helping patients and physicians find answers and take action.

As part of Foundation Medicine's Advancing Inclusive Diagnostics Initiative, a formal Call for Grants Notification (CGN) will be issued in Q4 2022.

The CGN will focus on projects/initiatives aimed at increasing biomarker testing education, awareness, and access among underserved populations in the United States.

Addressing disparities in oncology care requires multi-stakeholder collaboration; only applications which include a collaboration between two separate organizations will be considered.

Applicants must be U.S.-based and each applicant's organization must be recognized by the IRS as a tax exempt, public charity under section 501(c)(3) of the Internal Revenue Code and must be located in the United States.



Please email advancinginclusivediagnostics@foundationmedicine.com to receive updates and instructions about the official application process.

References:

1. Schwaederle M, Zhao M, Lee JJ et al.. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. *JAMA Oncol* 2016;2:1452-1459.
2. Polite, BN, L. Adams-Campbell, O. Brawley, et al. "Charting the Future of Cancer Health Disparities Research: A Position Statement for the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute" *Cancer Research*. 2017; 77(17) 4548-4555
3. L.E.K. interviews and analysis FMI-purchased Kantar data, SEER, MedPanel 'Assessment of Market for Pan-Cancer Testing Wave 2', IMS Health Medical Claims Data (DX) dataset (April 2015 to Dec 2016)